Sex hormones and androgen receptor: Risk factors of coronary heart disease in elderly men

Chinese Medical Sciences Journal

Volumn 25, Issue 1, 2010, Pages 44-49

  Cao, Jian ^a   Zou, Hui ^a   Zhu, Bing Po ^a   Wang, Hao ^a   Li, Jian ^a   Ding, Yu ^a   Li, Xiao Ying ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Androgen receptor; Coronary heart disease; Elderly; Sex steroid hormone; Testosterone

Indexed keywords

ANDROGEN RECEPTOR; ESTRADIOL; FOLLITROPIN; LUTEINIZING HORMONE; PRASTERONE SULFATE; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; AGED; AGING; ARTICLE; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ESTRADIOL BLOOD LEVEL; FLOW CYTOMETRY; FLUORESCENCE; FOLLITROPIN BLOOD LEVEL; GROUPS BY AGE; HUMAN; ISCHEMIC HEART DISEASE; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TESTOSTERONE BLOOD LEVEL;

EID: 77952086429     PISSN: 10019294     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1001-9294(10)60019-3     Document Type: Article

References (30)

1. Schreiner PJ, Niemela M, Miettinen H, et al. Gender differences in recurrent coronary events; the FINMONICA MI register. Eur Heart J 2001; 22:762-768
2. Death AK, McGrath KC, Sader MA, et al. Dihydrotestosterone promotes vascular cell adhesionmolecule-1 expression in male human endothelial cells via a nuclear factor-B-dependent pathway. Endocrinology 2004; 145:1889-1897
3. Bruck B, Brehme U, Gugel N, et al. Gender-specific differences in the effects of testosterone and estrogen on the development of atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 1997; 17:2192-2199
4. Alexandersen P, Karsdal MA, Christiansen C. Long-term prevention with hormone-replacement therapy after the menopause: which women should be targeted? Womens Health (Lond Engl) 2009; 5:637-647
5. Prentice RL, Manson JE, Langer RD, et al. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol 2009; 170:12-23.
6. English KM, Mandour O, Steeds RP, et al. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J 2000; 21:890-894
7. Malkin CJ, Pugh PJ, Morris PD, et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart 2004; 90:871-876
8. Vermeulen A, Kaufman JM. Ageing of the hypothalamo-pituitary-testicular axis in men. Horm Res 1995; 43:25-28
9. Turhan S, Tulunay C, Güleç S, et al. The association between androgen levels and premature coronary artery disease in men. Coron Artery Dis 2007; 18:159-162
10. Dunajska K, Milewicz A, Szymczak J, et al. Evaluation of sex hormone levels and some metabolic factors in men with coronary atherosclerosis. Aging Male 2004; 7:197-204.
11. Nathan L, Shi W, Dinh H, et al. Testosterone inhibits early atherogenesis by conversion to estradiol: critical role of aromatase. Proc Natl Acad Sci U S A 2001; 98:3589-3593
12. Zgliczynski S, Ossowski M, Slowinska-Srzednicka J, et al. Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men. Atherosclerosis 1996; 121:35-43.
13. Rosano GM, Leonardo F, Pagnotta P, et al. Acute antiischemic effect of testosterone in men with coronary artery disease. Circulation1999; 99:1666-1670
14. Channer KS, Jones TH. Cardiovascular effects of testosterone: implications of the "male menopause"? Heart 2003; 89:121-122
15. English KM, Jones RD, Jones TH, et al. Testosterone acts as a coronary vasodilator by a calcium antagonistic action. J Endocrinol Invest 2002; 25:455-458
16. Platz EA, Rimm EB, Willett WC, et al. Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J Natl Cancer Inst 2000; 92:2009-2017
17. Härkönen K, Huhtaniemi I, Mäkinen J, et al. The polymorphic androgen receptor gene CAG repeat, pituitary-testicular function and andropausal symptoms in ageing men. Int J Androl 2003; 26:187-194
18. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocrin Rev 2005; 26:833-876
19. Simon D, Charles MA, Nahoul K, et al. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom Study. J Clin Endocrinol Metab 1997; 82:682-685
20. Stellato RK, Feldman HA, Hamdy O, et al. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care 2000; 23:490-494
21. Phillips GB, Pinkernell BH, Jing TY. The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb 1994; 14:701-706
22. Yang XC, Jing TY, Resnick LM, et al. Relation of hemostatic risk factors to other risk factors for coronary heart disease and to sex hormones in men. Arterioscler Thromb 1993; 13:467-471
23. Caron P, Bennet A, Camare R, et al. Plasminogen activator inhibitor in plasma is related to testosterone in men. Metabolism 1989; 38:1010-1015
24. Glueck CJ, Glueck HI, Stroop D, et al. Endogenous testosterone, fibrinolysis, and coronary heart disease risk in hyperlipidemic men. J Lab Clin Med 1993; 122:412-420
25. Hanke H, Lenz C, Hess B, et al. Effect of testosterone on plaque development and androgen receptor expression in the arterial vessel wall. Circulation 2001; 103:1382-1385
26. Khaw KT, Barrett-Connor E. Blood pressure and endogenous testosterone in men: an inverse relationship. J Hypertens 1988; 6:329-332
27. Morano I, Gerstner J, Rüegg JC, et al. Regulation of myosin heavy chain expression in the hearts of hypertensive rats by testosterone. Circ Res 1990; 66:1585-1590 (Pubitemid 20178707)
28. Wakasugi M, Noguchi T, Kazama YI, et al. The effects of sex hormones on the synthesis of prostacyclin (PGI2) by vascular tissues. Prostaglandins 1989; 37:401-410
29. Schneider G, Kirschner M, Berkowitz R, et al. Increased estrogen production in obese men. J Clin Endocrinol Metab 1979; 48:633-638
30. Cohen PG. The hypogonadal-obesity cycle: role of aromatase in modulating the testosterone-estradiol shunt - a major factor in the genesis of morbid obesity. Med Hypotheses 1999; 52:49-51.